Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

ClinicalTrials.gov ID: NCT04122170

Public ClinicalTrials.gov record NCT04122170. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old

Study identification

NCT ID
NCT04122170
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Enrollment
207 participants

Conditions and interventions

Conditions

Interventions

  • Ticagrelor Oral Tablet - Pre-Treatment Drug
  • Aspirin (ASA) Oral Tablet - Pre-Treatment Drug
  • Bentracimab (PB2452) Infusion Drug
  • Placebo (0.9% Sodium chloride) infusion Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 80 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 23, 2019
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update posted
Apr 7, 2024

2019 – 2021

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Woodland Research Northwest, LLC Rogers Arkansas 72758
WCCT Global, Inc. Cypress California 90630
Pacific Research Network San Diego California 92103
Clinical Pharmacology of Miami, LLC Miami Florida 33014-3616
PPD Development, LP Orlando Florida 32806
Altasciences Clinical Kansas, Inc. Overland Park Kansas 66212
BioPharma Services USA Inc. (BPSUSA) St Louis Missouri 63141
Monroe Biomedical Research Monroe North Carolina 28112
Aventiv Research Inc. Columbus Ohio 43213
Remington-Davis, Inc. Columbus Ohio 43215
VitaLink Research - Greenville Greenville South Carolina 29615
VitaLink Research - Spartanburg Spartanburg South Carolina 29303
Rebecca Wood-Horrall Austin Texas 78744

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04122170, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2024 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04122170 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →